BeiGeneius - Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?
VIDEO 1:28:45 10/2021
BeiGeneius - Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?
Monday, September 27, 2021 | 17:30–19:00 (CEST)
Wojciech Jurczak
Maria Skłodowska-Curie National Research Institute of Oncology, Poland
Paolo Ghia
The Vita-Salute San Raffaele University, Italy
Federico Pea
University of Bologna, Italy
Alessandra Tedeschi
Niguarda Cancer Center, Italy
Rating
